Symbols / IBRX Stock $8.19 +1.49% ImmunityBio, Inc.
IBRX (Stock) Chart
About
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 8.46B | Enterprise Value | 9.02B | Income | -351.40M | Sales | 113.29M | Book/sh | -0.49 | Cash/sh | 0.24 |
| Dividend Yield | — | Payout | 0.00% | Employees | 684 | IPO | — | P/E | — | Forward P/E | -409.50 |
| PEG | — | P/S | 74.66 | P/B | -16.55 | P/C | — | EV/EBITDA | -37.50 | EV/Sales | 79.65 |
| Quick Ratio | 4.62 | Current Ratio | 5.10 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -0.38 | EPS next Y | -0.02 |
| EPS Growth | — | Revenue Growth | 4.07% | Earnings | 2026-05-11 | ROA | -36.17% | ROE | — | ROIC | — |
| Gross Margin | 99.33% | Oper. Margin | -168.95% | Profit Margin | 0.00% | Shs Outstand | 1.03B | Shs Float | 377.71M | Short Float | 35.80% |
| Short Ratio | 4.93 | Short Interest | — | 52W High | 12.43 | 52W Low | 1.83 | Beta | 0.06 | Avg Volume | 28.49M |
| Volume | 9.23M | Target Price | $14.80 | Recom | Strong_buy | Prev Close | $8.07 | Price | $8.19 | Change | 1.49% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-21 | main | D. Boral Capital | Buy → Buy | $23 |
| 2026-04-08 | main | D. Boral Capital | Buy → Buy | $23 |
| 2026-03-26 | main | D. Boral Capital | Buy → Buy | $23 |
| 2026-03-23 | main | D. Boral Capital | Buy → Buy | $23 |
| 2026-03-17 | main | D. Boral Capital | Buy → Buy | $23 |
| 2026-03-09 | main | D. Boral Capital | Buy → Buy | $23 |
| 2026-03-04 | reit | Piper Sandler | Overweight → Overweight | $12 |
| 2026-02-23 | main | D. Boral Capital | Buy → Buy | $23 |
| 2026-02-23 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2026-02-19 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-02-17 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-01-26 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2026-01-23 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-01-23 | main | BTIG | Buy → Buy | $9 |
| 2026-01-20 | main | Piper Sandler | Overweight → Overweight | $7 |
| 2026-01-20 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-01-16 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-01-13 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-12-16 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-12-12 | main | Jefferies | Buy → Buy | $9 |
- IBRX stock extends rally: Founder flags fresh bull case for Anktiva on breast cancer immune signal - MSN hu, 23 Apr 2026 19
- IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results - Yahoo Finance Fri, 10 Apr 2026 07
- IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt - PR Newswire hu, 23 Apr 2026 13
- IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims - Yahoo Finance Wed, 25 Mar 2026 07
- IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After FDA Allegedly Exposed Misleading Claims: Levi & Korsinsky - PR Newswire Wed, 22 Apr 2026 13
- IBRX stock still a buy after worst day in over a year? Why this analyst is shrugging off FDA warning letter - MSN hu, 23 Apr 2026 16
- IBRX stock in spotlight as FDA scrutiny prompts ImmunityBio to withdraw content, tighten oversight - MSN hu, 23 Apr 2026 09
- IBRX stock rally not over yet? Chairman says Trump diplomacy led to ‘amazing results’ for cancer drug - MSN hu, 23 Apr 2026 04
- IBRX stock has quadrupled this year – and now the much-talked-about Anktiva has entered Saudi Arabia - MSN Wed, 22 Apr 2026 02
- IBRX Stock Has Quadrupled This Year – And Its Breakout Cancer Drug Has Hit A New Market - Stocktwits ue, 21 Apr 2026 12
- IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA - GlobeNewswire hu, 23 Apr 2026 01
- IBRX Stock Extends Rally: Founder Flags Fresh Bull Case For Anktiva On Breast Cancer Immune Signal - Stocktwits ue, 21 Apr 2026 15
- IBRX stock gains steam: Founder teases balance sheet ‘strengthening’ and global push as bears finally step back - MSN ue, 21 Apr 2026 13
- Is ImmunityBio’s (IBRX) FDA Promotion Setback Reframing the Stock’s Risk and Credibility Narrative? - Yahoo Finance ue, 07 Apr 2026 07
- $IBRX stock is down 4% today. Here's what we see in our data. - Quiver Quantitative Wed, 01 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
113.29
+668.31%
|
14.74
+2270.58%
|
0.62
+159.17%
|
0.24
|
| Operating Revenue |
|
112.98
+698.46%
|
14.15
|
0.00
|
0.00
|
| Cost Of Revenue |
|
0.75
|
0.00
|
0.00
|
0.00
|
| Reconciled Cost Of Revenue |
|
0.75
|
0.00
|
0.00
|
0.00
|
| Gross Profit |
|
112.53
+663.21%
|
14.74
+2270.58%
|
0.62
+159.17%
|
0.24
|
| Operating Expense |
|
368.56
+2.68%
|
358.93
-0.85%
|
361.99
+3.17%
|
350.86
|
| Research And Development |
|
218.56
+14.94%
|
190.14
-18.17%
|
232.37
-6.36%
|
248.15
|
| Selling General And Administration |
|
150.00
-11.13%
|
168.78
+30.21%
|
129.62
+26.20%
|
102.71
|
| Total Expenses |
|
369.31
+2.89%
|
358.93
-0.85%
|
361.99
+3.17%
|
350.86
|
| Operating Income |
|
-256.03
+25.61%
|
-344.18
+4.75%
|
-361.36
-3.07%
|
-350.62
|
| Total Operating Income As Reported |
|
-256.03
+25.61%
|
-344.18
+4.99%
|
-362.25
-3.12%
|
-351.30
|
| EBITDA |
|
-223.56
+15.43%
|
-264.35
+44.76%
|
-478.58
-36.01%
|
-351.88
|
| Normalized EBITDA |
|
-282.76
+6.79%
|
-303.36
+29.51%
|
-430.36
-19.92%
|
-358.86
|
| Reconciled Depreciation |
|
15.53
-11.56%
|
17.55
-5.18%
|
18.51
+1.38%
|
18.26
|
| EBIT |
|
-239.08
+15.19%
|
-281.90
+43.29%
|
-497.09
-34.30%
|
-370.14
|
| Total Unusual Items |
|
59.20
+51.78%
|
39.01
+180.90%
|
-48.22
-790.70%
|
6.98
|
| Total Unusual Items Excluding Goodwill |
|
59.20
+51.78%
|
39.01
+180.90%
|
-48.22
-790.70%
|
6.98
|
| Special Income Charges |
|
0.00
|
0.00
+100.00%
|
-0.89
-30.10%
|
-0.68
|
| Impairment Of Capital Assets |
|
0.00
|
0.00
-100.00%
|
0.89
+30.10%
|
0.68
|
| Net Income |
|
-351.40
+15.03%
|
-413.56
+29.09%
|
-583.20
-40.00%
|
-416.57
|
| Pretax Income |
|
-351.61
+15.00%
|
-413.64
+29.16%
|
-583.89
-39.93%
|
-417.29
|
| Net Non Operating Interest Income Expense |
|
-109.84
+27.70%
|
-151.93
-18.38%
|
-128.34
-111.05%
|
-60.81
|
| Interest Expense Non Operating |
|
112.53
-14.59%
|
131.74
+51.77%
|
86.80
+84.12%
|
47.15
|
| Net Interest Income |
|
-109.84
+27.70%
|
-151.93
-18.38%
|
-128.34
-111.05%
|
-60.81
|
| Interest Expense |
|
112.53
-14.59%
|
131.74
+51.77%
|
86.80
+84.12%
|
47.15
|
| Interest Income Non Operating |
|
2.69
+12.04%
|
2.40
+178.10%
|
0.86
-68.13%
|
2.71
|
| Interest Income |
|
2.69
+12.04%
|
2.40
+178.10%
|
0.86
-68.13%
|
2.71
|
| Other Income Expense |
|
14.26
-82.71%
|
82.46
+187.55%
|
-94.19
-1506.84%
|
-5.86
|
| Other Non Operating Income Expenses |
|
-44.95
-203.43%
|
43.46
+213.09%
|
-38.43
-5120.92%
|
-0.74
|
| Gain On Sale Of Security |
|
59.20
+51.78%
|
39.01
+182.41%
|
-47.33
-717.75%
|
7.66
|
| Tax Provision |
|
-0.14
|
0.00
+100.00%
|
-0.04
-217.65%
|
0.03
|
| Tax Rate For Calcs |
|
0.00
|
0.00
-100.00%
|
0.00
-99.97%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
+100.00%
|
-0.00
-100.23%
|
1.47
|
| Net Income Including Noncontrolling Interests |
|
-351.47
+15.03%
|
-413.64
+29.15%
|
-583.85
-39.91%
|
-417.32
|
| Net Income From Continuing Operation Net Minority Interest |
|
-351.40
+15.03%
|
-413.56
+29.09%
|
-583.20
-40.00%
|
-416.57
|
| Net Income From Continuing And Discontinued Operation |
|
-351.40
+15.03%
|
-413.56
+29.09%
|
-583.20
-40.00%
|
-416.57
|
| Net Income Continuous Operations |
|
-351.47
+15.03%
|
-413.64
+29.15%
|
-583.85
-39.91%
|
-417.32
|
| Minority Interests |
|
0.07
-8.64%
|
0.08
-87.65%
|
0.66
-12.88%
|
0.75
|
| Normalized Income |
|
-410.60
+9.27%
|
-452.57
+15.40%
|
-534.98
-26.75%
|
-422.08
|
| Net Income Common Stockholders |
|
-351.40
+15.03%
|
-413.56
+29.09%
|
-583.20
-40.00%
|
-416.57
|
| Diluted EPS |
|
-0.38
+38.71%
|
-0.62
+46.09%
|
-1.15
-10.58%
|
-1.04
|
| Basic EPS |
|
-0.38
+35.59%
|
-0.59
+48.70%
|
-1.15
-10.58%
|
-1.04
|
| Basic Average Shares |
|
919.86
+31.92%
|
697.31
+37.09%
|
508.64
+27.19%
|
399.90
|
| Diluted Average Shares |
|
919.86
+31.33%
|
700.44
+37.71%
|
508.64
+27.19%
|
399.90
|
| Diluted NI Availto Com Stockholders |
|
-351.40
+15.03%
|
-413.56
+29.09%
|
-583.20
-40.00%
|
-416.57
|
| Earnings From Equity Interest |
|
0.00
|
0.00
+100.00%
|
-7.55
+37.65%
|
-12.11
|
| Securities Amortization |
|
—
|
—
|
-1.84
-224.09%
|
1.49
|
| Total Other Finance Cost |
|
—
|
22.59
-46.72%
|
42.40
+158.99%
|
16.37
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
501.90
+31.07%
|
382.93
-24.09%
|
504.45
+39.21%
|
362.36
|
| Current Assets |
|
314.88
+70.58%
|
184.59
-37.23%
|
294.08
+109.20%
|
140.58
|
| Cash Cash Equivalents And Short Term Investments |
|
242.82
+62.09%
|
149.81
-43.78%
|
266.46
+148.60%
|
107.18
|
| Cash And Cash Equivalents |
|
88.33
-38.41%
|
143.43
-45.97%
|
265.45
+153.68%
|
104.64
|
| Other Short Term Investments |
|
154.48
+2321.00%
|
6.38
+532.41%
|
1.01
-60.32%
|
2.54
|
| Receivables |
|
42.62
+1506.37%
|
2.65
-16.26%
|
3.17
+67.62%
|
1.89
|
| Accounts Receivable |
|
42.57
+1703.86%
|
2.36
|
0.00
|
—
|
| Other Receivables |
|
—
|
—
|
1.15
|
—
|
| Inventory |
|
0.91
-89.00%
|
8.27
|
0.00
|
—
|
| Raw Materials |
|
—
|
0.00
|
0.00
|
—
|
| Work In Process |
|
—
|
7.50
|
0.00
|
—
|
| Finished Goods |
|
—
|
0.77
|
0.00
|
—
|
| Prepaid Assets |
|
26.39
+17.06%
|
22.55
+3.30%
|
21.83
-23.69%
|
28.60
|
| Other Current Assets |
|
2.13
+63.85%
|
1.30
-50.36%
|
2.62
-9.45%
|
2.90
|
| Total Non Current Assets |
|
187.02
-5.71%
|
198.35
-5.71%
|
210.37
-5.15%
|
221.78
|
| Net PPE |
|
147.27
-13.60%
|
170.46
-6.66%
|
182.62
-3.60%
|
189.45
|
| Gross PPE |
|
259.76
-3.81%
|
270.05
+1.14%
|
267.00
+3.21%
|
258.70
|
| Accumulated Depreciation |
|
-112.48
-12.95%
|
-99.59
-18.03%
|
-84.38
-21.84%
|
-69.25
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
—
|
—
|
| Machinery Furniture Equipment |
|
3.92
+9.94%
|
3.56
+0.20%
|
3.56
-0.22%
|
3.56
|
| Construction In Progress |
|
86.43
+0.02%
|
86.42
+2.35%
|
84.44
+16.15%
|
72.69
|
| Other Properties |
|
96.27
-9.98%
|
106.94
+0.45%
|
106.46
-6.40%
|
113.73
|
| Leases |
|
73.14
+0.02%
|
73.13
+0.79%
|
72.55
+5.59%
|
68.71
|
| Goodwill And Other Intangible Assets |
|
13.95
-12.43%
|
15.93
-6.79%
|
17.09
-14.55%
|
20.00
|
| Goodwill |
|
0.91
+0.00%
|
0.91
|
—
|
—
|
| Other Intangible Assets |
|
13.04
-13.18%
|
15.02
-12.11%
|
17.09
-14.55%
|
20.00
|
| Investments And Advances |
|
—
|
0.00
-100.00%
|
0.89
+6.07%
|
0.84
|
| Long Term Equity Investment |
|
—
|
—
|
—
|
0.84
|
| Other Investments |
|
—
|
—
|
—
|
4.86
|
| Other Non Current Assets |
|
18.42
+281.52%
|
4.83
+67.60%
|
2.88
-40.74%
|
4.86
|
| Total Liabilities Net Minority Interest |
|
1,001.47
+14.97%
|
871.06
-20.11%
|
1,090.39
+34.26%
|
812.18
|
| Current Liabilities |
|
61.75
+12.39%
|
54.94
-5.73%
|
58.28
-88.36%
|
500.86
|
| Payables And Accrued Expenses |
|
31.08
-1.03%
|
31.40
-9.58%
|
34.73
-25.43%
|
46.57
|
| Payables |
|
7.38
+7.00%
|
6.90
-33.23%
|
10.33
-57.81%
|
24.48
|
| Accounts Payable |
|
6.98
+3.76%
|
6.72
-26.86%
|
9.20
-56.25%
|
21.02
|
| Current Accrued Expenses |
|
23.70
-3.30%
|
24.50
+0.43%
|
24.40
+10.47%
|
22.09
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
20.07
+33.56%
|
15.03
-14.59%
|
17.59
-2.86%
|
18.11
|
| Current Debt And Capital Lease Obligation |
|
7.54
+0.92%
|
7.47
+42.37%
|
5.24
-98.79%
|
434.55
|
| Current Debt |
|
—
|
—
|
—
|
431.90
|
| Other Current Borrowings |
|
—
|
—
|
—
|
431.90
|
| Current Capital Lease Obligation |
|
7.54
+0.92%
|
7.47
+42.37%
|
5.24
+97.89%
|
2.65
|
| Other Current Liabilities |
|
3.07
+192.67%
|
1.05
+46.65%
|
0.72
-56.02%
|
1.63
|
| Total Non Current Liabilities Net Minority Interest |
|
939.72
+15.14%
|
816.12
-20.93%
|
1,032.11
+231.53%
|
311.31
|
| Long Term Debt And Capital Lease Obligation |
|
510.54
+2.79%
|
496.70
-31.16%
|
721.48
+149.46%
|
289.22
|
| Long Term Debt |
|
477.09
+3.29%
|
461.88
-32.23%
|
681.54
+182.48%
|
241.27
|
| Long Term Capital Lease Obligation |
|
33.45
-3.95%
|
34.82
-12.82%
|
39.94
-16.70%
|
47.95
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
—
|
—
|
—
|
—
|
| Other Non Current Liabilities |
|
325.04
+14.16%
|
284.72
+81.90%
|
156.52
+34150.33%
|
0.46
|
| Stockholders Equity |
|
-500.47
-2.32%
|
-489.10
+16.68%
|
-586.99
-31.22%
|
-447.33
|
| Common Stock Equity |
|
-500.47
-2.32%
|
-489.10
+16.68%
|
-586.99
-31.22%
|
-447.33
|
| Capital Stock |
|
0.10
+18.82%
|
0.09
+26.87%
|
0.07
+59.52%
|
0.04
|
| Common Stock |
|
0.10
+18.82%
|
0.09
+26.87%
|
0.07
+59.52%
|
0.04
|
| Share Issued |
|
1,011.96
+18.63%
|
853.07
+27.13%
|
671.03
+59.11%
|
421.73
|
| Ordinary Shares Number |
|
1,011.80
+18.63%
|
852.90
+27.13%
|
670.87
+59.14%
|
421.57
|
| Treasury Shares Number |
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
|
| Additional Paid In Capital |
|
3,197.12
+10.82%
|
2,884.87
+21.49%
|
2,374.62
+22.98%
|
1,930.94
|
| Retained Earnings |
|
-3,726.65
-10.41%
|
-3,375.25
-13.96%
|
-2,961.68
-24.52%
|
-2,378.49
|
| Gains Losses Not Affecting Retained Earnings |
|
28.96
+2317.03%
|
1.20
+11880.00%
|
0.01
-94.54%
|
0.18
|
| Minority Interest |
|
0.90
-7.64%
|
0.97
-7.71%
|
1.05
+142.12%
|
-2.49
|
| Other Equity Adjustments |
|
28.96
+2317.03%
|
1.20
+11880.00%
|
0.01
-94.54%
|
0.18
|
| Total Equity Gross Minority Interest |
|
-499.57
-2.34%
|
-488.13
+16.69%
|
-585.94
-30.26%
|
-449.82
|
| Total Capitalization |
|
-23.38
+14.13%
|
-27.22
-128.79%
|
94.55
+145.89%
|
-206.06
|
| Working Capital |
|
253.12
+95.25%
|
129.64
-45.02%
|
235.80
+165.45%
|
-360.28
|
| Invested Capital |
|
-23.38
+14.13%
|
-27.22
-128.79%
|
94.55
-58.14%
|
225.84
|
| Total Debt |
|
518.08
+2.76%
|
504.17
-30.62%
|
726.72
+0.41%
|
723.77
|
| Net Debt |
|
388.76
+22.08%
|
318.45
-23.47%
|
416.08
-26.81%
|
568.53
|
| Capital Lease Obligations |
|
40.98
-3.09%
|
42.29
-6.41%
|
45.19
-10.70%
|
50.60
|
| Net Tangible Assets |
|
-514.42
-1.86%
|
-505.03
+16.40%
|
-604.08
-29.26%
|
-467.33
|
| Tangible Book Value |
|
-514.42
-1.86%
|
-505.03
+16.40%
|
-604.08
-29.26%
|
-467.33
|
| Available For Sale Securities |
|
—
|
—
|
0.89
+6.07%
|
0.84
|
| Current Notes Payable |
|
—
|
—
|
—
|
—
|
| Derivative Product Liabilities |
|
104.14
+200.16%
|
34.70
-77.49%
|
154.10
+612.25%
|
21.64
|
| Duefrom Related Parties Current |
|
0.05
-84.30%
|
0.29
-85.49%
|
2.02
+6.83%
|
1.89
|
| Dueto Related Parties Current |
|
0.40
+132.95%
|
0.17
-84.77%
|
1.14
-67.25%
|
3.47
|
| Investmentin Financial Assets |
|
—
|
0.00
-100.00%
|
0.89
+6.07%
|
0.84
|
| Non Current Note Receivables |
|
7.38
+3.51%
|
7.13
+3.65%
|
6.88
+3.77%
|
6.63
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-304.94
+22.06%
|
-391.24
-6.67%
|
-366.76
-8.67%
|
-337.51
|
| Cash Flow From Continuing Operating Activities |
|
-304.94
+22.06%
|
-391.24
-6.67%
|
-366.76
-8.67%
|
-337.51
|
| Net Income From Continuing Operations |
|
-351.47
+15.03%
|
-413.64
+29.15%
|
-583.85
-39.91%
|
-417.32
|
| Depreciation Amortization Depletion |
|
15.53
-11.56%
|
17.55
-5.18%
|
18.51
+1.38%
|
18.26
|
| Depreciation And Amortization |
|
15.53
-11.56%
|
17.55
-5.18%
|
18.51
+1.38%
|
18.26
|
| Other Non Cash Items |
|
90.58
+275.31%
|
24.13
-74.23%
|
93.64
+165.19%
|
35.31
|
| Stock Based Compensation |
|
36.81
+6.90%
|
34.43
-29.96%
|
49.16
+22.36%
|
40.18
|
| Asset Impairment Charge |
|
14.02
|
0.00
-100.00%
|
0.89
-56.01%
|
2.01
|
| Deferred Tax |
|
—
|
—
|
—
|
-0.00
|
| Deferred Income Tax |
|
—
|
—
|
—
|
-0.00
|
| Operating Gains Losses |
|
-53.32
-59.49%
|
-33.43
-167.39%
|
49.61
+468.57%
|
-13.46
|
| Gain Loss On Investment Securities |
|
-53.32
-59.49%
|
-33.43
-167.39%
|
49.61
+468.57%
|
-13.46
|
| Unrealized Gain Loss On Investment Securities |
|
0.00
-100.00%
|
0.63
-60.28%
|
1.59
-62.03%
|
4.19
|
| Change In Working Capital |
|
-54.33
-179.73%
|
-19.42
-607.37%
|
3.83
+147.84%
|
-8.00
|
| Change In Receivables |
|
-40.21
-1603.86%
|
-2.36
|
0.00
|
0.00
|
| Changes In Account Receivables |
|
-40.21
-1603.86%
|
-2.36
|
0.00
|
0.00
|
| Change In Inventory |
|
-6.33
+23.54%
|
-8.27
|
0.00
|
0.00
|
| Change In Prepaid Assets |
|
-4.86
-385.20%
|
1.70
-71.42%
|
5.96
+135.98%
|
-16.56
|
| Change In Payables And Accrued Expense |
|
2.99
+164.04%
|
-4.67
-2294.84%
|
0.21
-98.24%
|
12.10
|
| Change In Accrued Expense |
|
3.18
+311.14%
|
-1.51
-122.54%
|
6.69
+63.07%
|
4.10
|
| Change In Payable |
|
-0.19
+94.00%
|
-3.17
+51.10%
|
-6.48
-180.95%
|
8.00
|
| Change In Account Payable |
|
-0.19
+94.00%
|
-3.17
+51.10%
|
-6.48
-180.95%
|
8.00
|
| Change In Other Working Capital |
|
0.48
-37.48%
|
0.76
+167.58%
|
-1.13
+7.84%
|
-1.23
|
| Change In Other Current Assets |
|
0.80
+172.47%
|
-1.11
-162.81%
|
1.76
-11.71%
|
2.00
|
| Change In Other Current Liabilities |
|
-7.21
-31.74%
|
-5.47
-83.78%
|
-2.98
+31.05%
|
-4.32
|
| Investing Cash Flow |
|
-149.80
-1123.26%
|
-12.25
+59.81%
|
-30.47
-211.62%
|
27.30
|
| Cash Flow From Continuing Investing Activities |
|
-149.80
-1123.26%
|
-12.25
+59.81%
|
-30.47
-211.62%
|
27.30
|
| Net PPE Purchase And Sale |
|
-3.85
+44.16%
|
-6.89
+77.48%
|
-30.58
+60.87%
|
-78.16
|
| Purchase Of PPE |
|
-3.85
+44.16%
|
-6.89
+77.48%
|
-30.58
+60.87%
|
-78.16
|
| Sale Of PPE |
|
—
|
—
|
0.00
|
0.00
|
| Capital Expenditure |
|
-4.25
+38.27%
|
-6.89
+77.48%
|
-30.58
+69.23%
|
-99.39
|
| Net Investment Purchase And Sale |
|
-145.55
-3239.81%
|
-4.36
-3922.81%
|
0.11
-99.91%
|
127.69
|
| Purchase Of Investment |
|
-241.37
-71.23%
|
-140.97
-1260.93%
|
-10.36
+69.81%
|
-34.31
|
| Sale Of Investment |
|
95.82
-29.85%
|
136.61
+1204.50%
|
10.47
-93.54%
|
162.00
|
| Net Business Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-1.00
|
| Purchase Of Business |
|
—
|
0.00
|
0.00
+100.00%
|
-1.00
|
| Net Intangibles Purchase And Sale |
|
-0.41
|
0.00
|
0.00
+100.00%
|
-21.23
|
| Purchase Of Intangibles |
|
-0.41
|
0.00
|
0.00
+100.00%
|
-21.23
|
| Net Other Investing Changes |
|
—
|
-1.00
|
—
|
—
|
| Financing Cash Flow |
|
400.24
+42.12%
|
281.63
-49.56%
|
558.34
+139.00%
|
233.61
|
| Cash Flow From Continuing Financing Activities |
|
400.24
+42.12%
|
281.63
-49.56%
|
558.34
+139.00%
|
233.61
|
| Net Issuance Payments Of Debt |
|
2.86
+4562.50%
|
-0.06
-100.02%
|
258.62
+48.58%
|
174.07
|
| Issuance Of Debt |
|
2.88
|
0.00
-100.00%
|
258.70
+48.57%
|
174.12
|
| Repayment Of Debt |
|
-0.03
+56.25%
|
-0.06
+16.88%
|
-0.08
-32.76%
|
-0.06
|
| Long Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
258.70
+48.57%
|
174.12
|
| Long Term Debt Payments |
|
-0.03
+56.25%
|
-0.06
+16.88%
|
-0.08
-32.76%
|
-0.06
|
| Net Long Term Debt Issuance |
|
-0.03
+56.25%
|
-0.06
-100.02%
|
258.62
+48.58%
|
174.07
|
| Short Term Debt Issuance |
|
2.88
|
0.00
|
0.00
-100.00%
|
174.12
|
| Net Short Term Debt Issuance |
|
2.88
|
0.00
|
0.00
-100.00%
|
174.12
|
| Net Common Stock Issuance |
|
400.56
+259.71%
|
111.36
+10.74%
|
100.56
+66.42%
|
60.43
|
| Common Stock Payments |
|
—
|
—
|
—
|
—
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
-2.04
-102.79%
|
73.38
+1047.83%
|
6.39
+1279.52%
|
-0.54
|
| Net Other Financing Charges |
|
-1.13
-101.17%
|
96.96
-49.70%
|
192.76
+56962.54%
|
-0.34
|
| Changes In Cash |
|
-54.50
+55.28%
|
-121.85
-175.63%
|
161.11
+310.33%
|
-76.60
|
| Effect Of Exchange Rate Changes |
|
0.01
+165.22%
|
-0.02
+92.12%
|
-0.29
-202.82%
|
0.28
|
| Beginning Cash Position |
|
143.91
-45.85%
|
265.79
+153.21%
|
104.97
-42.10%
|
181.28
|
| End Cash Position |
|
89.43
-37.86%
|
143.91
-45.85%
|
265.79
+153.21%
|
104.97
|
| Free Cash Flow |
|
-309.19
+22.34%
|
-398.12
-0.20%
|
-397.34
+9.05%
|
-436.90
|
| Interest Paid Supplemental Data |
|
71.32
-22.74%
|
92.32
+19.60%
|
77.19
+117.80%
|
35.44
|
| Income Tax Paid Supplemental Data |
|
0.00
-100.00%
|
0.01
+87.50%
|
0.01
+300.00%
|
0.00
|
| Amortization Of Securities |
|
-2.75
-84.35%
|
-1.49
-986.86%
|
-0.14
-110.39%
|
1.32
|
| Common Stock Issuance |
|
400.56
+259.71%
|
111.36
+10.74%
|
100.56
+66.42%
|
60.43
|
| Earnings Losses From Equity Investments |
|
—
|
—
|
—
|
—
|
| Issuance Of Capital Stock |
|
400.56
+259.71%
|
111.36
+10.74%
|
100.56
+66.42%
|
60.43
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-09 View
- 8-K2026-04-06 View
- 42026-04-02 View
- 8-K2026-03-31 View
- 42026-02-26 View
- 42026-02-24 View
- 42026-02-24 View
- 42026-02-24 View
- 42026-02-24 View
- 42026-02-24 View
- 42026-02-24 View
- 10-K2026-02-23 View
- 8-K2026-02-23 View
- 8-K2026-02-18 View
- 42026-02-12 View
- 42026-02-12 View
- 42026-02-12 View
- 42026-02-12 View
- 8-K2026-01-26 View
- 42026-01-21 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|